Get the Stockscreener App
114.50
0.60%
-0.79
Overview
News
Price History
Option Chain
Financials
Discussions
Forecast
Stock Split
Dividend History
Abbott Laboratories stock is traded at $114.50, with a volume of 1.72M.
It is down -0.60% in the last 24 hours and up +6.68% over the past month.
Abbott manufactures and markets cardiovascular and diabetes devices, adult and pediatric nutritional products, diagnostic equipment and testing kits, and branded generic drugs. Products include pacemakers, implantable cardioverter defibrillators, neuromodulation devices, coronary stents, catheters, infant formula, nutritional liquids for adults, continuous glucose monitors, and immunoassays and point-of-care diagnostic equipment. Abbott derives roughly 60% of sales outside the United States.
See More
Previous Close:
$115.29
Open:
$115.055
24h Volume:
1.72M
Relative Volume:
0.20
Market Cap:
$199.20B
Revenue:
$44.33B
Net Income/Loss:
$6.50B
P/E Ratio:
30.80
EPS:
3.717
Net Cash Flow:
$7.40B
1W Performance:
+2.08%
1M Performance:
+6.68%
6M Performance:
-13.57%
1Y Performance:
-15.08%
1-Day Range:
$113.82
$115.37
1-Week Range:
$111.18
$115.37
52-Week Range:
$105.27
$140.84
Abbott Laboratories Stock (ABT) Company Profile
Name
Abbott Laboratories
Sector
Industry
Phone
(224) 667-6100
Address
100 ABBOTT PARK ROAD, ABBOTT PARK, IL
Compare ABT vs SYK, MDT, BSX, EW
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
ABT
Abbott Laboratories
|
114.56 | 200.47B | 44.33B | 6.50B | 7.40B | 3.717 |
|
SYK
Stryker Corp
|
380.27 | 147.23B | 25.12B | 3.25B | 4.28B | 8.3984 |
|
MDT
Medtronic Plc
|
97.55 | 126.42B | 35.48B | 4.64B | 5.41B | 3.5856 |
|
BSX
Boston Scientific Corp
|
74.28 | 110.36B | 20.08B | 2.89B | 3.66B | 1.9391 |
|
EW
Edwards Lifesciences Corp
|
82.36 | 47.84B | 6.07B | 1.06B | 799.60M | 1.8527 |
Abbott Laboratories Stock (ABT) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Oct-10-25 | Initiated | The Benchmark Company | Buy |
| Jul-18-25 | Upgrade | Jefferies | Hold → Buy |
| Jun-16-25 | Initiated | Leerink Partners | Market Perform |
| Oct-08-24 | Initiated | Oppenheimer | Outperform |
| Sep-19-24 | Initiated | Piper Sandler | Overweight |
| Jul-30-24 | Downgrade | Edward Jones | Buy → Hold |
| May-30-24 | Initiated | Goldman | Buy |
| Jul-21-23 | Upgrade | Wolfe Research | Underperform → Peer Perform |
| May-30-23 | Downgrade | Morgan Stanley | Overweight → Equal-Weight |
| Apr-20-23 | Reiterated | Barclays | Overweight |
| Apr-20-23 | Reiterated | Bernstein | Outperform |
| Apr-20-23 | Reiterated | JP Morgan | Overweight |
| Apr-20-23 | Reiterated | Raymond James | Outperform |
| Apr-20-23 | Reiterated | UBS | Buy |
| Apr-20-23 | Reiterated | Wolfe Research | Underperform |
| Mar-29-23 | Initiated | UBS | Buy |
| Oct-26-22 | Initiated | Mizuho | Neutral |
| Oct-18-22 | Initiated | Barclays | Overweight |
| Oct-12-22 | Initiated | Jefferies | Hold |
| Jul-06-22 | Initiated | Wolfe Research | Underperform |
| Mar-02-22 | Resumed | BofA Securities | Buy |
| Jan-27-22 | Reiterated | Credit Suisse | Outperform |
| Jan-27-22 | Reiterated | Morgan Stanley | Overweight |
| Jan-27-22 | Reiterated | Raymond James | Outperform |
| Jan-27-22 | Reiterated | UBS | Buy |
| Dec-10-21 | Initiated | RBC Capital Mkts | Outperform |
| Oct-27-21 | Upgrade | Atlantic Equities | Neutral → Overweight |
| Oct-14-21 | Initiated | Redburn | Neutral |
| May-25-21 | Initiated | Barclays | Overweight |
| Apr-15-21 | Initiated | Atlantic Equities | Neutral |
| Jan-28-21 | Upgrade | BTIG Research | Neutral → Buy |
| Sep-11-20 | Initiated | Wolfe Research | Outperform |
| Jun-01-20 | Downgrade | Goldman | Neutral → Sell |
| Mar-05-20 | Initiated | Citigroup | Buy |
| Feb-13-20 | Initiated | Goldman | Neutral |
| Feb-06-20 | Resumed | BTIG Research | Neutral |
| Jan-02-20 | Downgrade | Guggenheim | Buy → Neutral |
| Jun-13-19 | Reiterated | BofA/Merrill | Buy |
| Feb-07-19 | Reiterated | BofA/Merrill | Buy |
| Jan-02-19 | Downgrade | Citigroup | Neutral → Sell |
| Nov-30-18 | Upgrade | Goldman | Neutral → Buy |
| Oct-16-18 | Initiated | Barclays | Overweight |
| Jun-27-18 | Initiated | Bernstein | Outperform |
| Jan-30-18 | Reiterated | Citigroup | Neutral |
| Jan-25-18 | Reiterated | Stifel | Buy |
| Jan-25-18 | Upgrade | William Blair | Mkt Perform → Outperform |
| Jan-03-18 | Initiated | Evercore ISI | Outperform |
| Jan-02-18 | Upgrade | JP Morgan | Neutral → Overweight |
| Jan-02-18 | Upgrade | Morgan Stanley | Equal-Weight → Overweight |
| Oct-19-17 | Reiterated | RBC Capital Mkts | Outperform |
| Oct-19-17 | Reiterated | Stifel | Buy |
View All
Abbott Laboratories Stock (ABT) Latest News
Point of Care Diagnostics Market Competitive Landscape Report 2025 Featuring Top 5 PlayersSysmex, Abbott Laboratories, Becton Dickinson and Co, Danaher, Quidel Diagnostics - Yahoo Finance
Cardiac Marker Testing Market Is Going to Boom |• Abbott • Roche - openPR.com
Is Abbott Laboratories (ABT) Pricing Reflect Long Term Value After Recent Share Price Weakness - Yahoo Finance
Abbott Laboratories Launches Landmark $20 Billion Bond Offering - AD HOC NEWS
ABT.SW Abbott Laboratories (SIX) down 13.50% pre-market: CHF86.50 support to watch - Meyka
Abbott (ABT) Ascends While Market Falls: Some Facts to Note - Nasdaq
Abbott Labs: A boring dividend machine that could quietly make you rich - MSN
Abbott Laboratories Kicks Off Bond Sale for Exact Sciences Deal - Bloomberg.com
Abbott Laboratories (ABT) Likely to Benefit From Nutrition Segment Recovery - Insider Monkey
Abbott Labs: A Boring Dividend Machine That Could Quietly Make You Rich - AOL.com
Key facts: Abbott Laboratories to raise $20 billion via bond sale; files for notes offering - TradingView
A Look At Abbott Laboratories (ABT) Valuation After Recent Share Price Moves - simplywall.st
Abbott Laboratories (ABT) Investor Outlook: Exploring A Promising 18.87% Potential Upside - DirectorsTalk Interviews
Global Neuromodulation Devices Market Anticipating Remarkable Growth at a CAGR of ~9% by 2032 | DelveInsight - GlobeNewswire Inc.
Abbott lines up one of the year's biggest bond sales at $20B - Crain's Chicago Business
Abbott Laboratories Stock (ABT) Opinions on Exact Sciences Acquisition - Quiver Quantitative
Abbott Laboratories (ABT) Plans $20B Bond Sale to Fund Exact Sci - GuruFocus
Abbott Laboratories (ABT) Stock Price, Trades & News - GuruFocus
Abbott kicks off bond sale for Exact Sciences deal - Modern Healthcare News
Abbott (ABT) Submits Automatic Mixed Securities Shelf Filing - GuruFocus
Abbott seeks $20 billion in US bond sale for Exact Sciences dealBloomberg News - marketscreener.com
Abbott files for eight-part notes offering, size not disclosedSEC filing - marketscreener.com
Abbott Labs Commences 8-Part Bond Sale Tied to Exact Sciences Acquisition - marketscreener.com
Abbott Laboratories Commences 8-Part Bond Sale Tied to Exact Sciences Acquisition, Bloomberg Reports - marketscreener.com
Health and Wellness Industry Report 2026-2035: A $10.35+ - GlobeNewswire
Health and Wellness Industry Report 2026-2035: A $10.35+ Trillion Market by 2030 Featuring Major Players Such as with Abbott Laboratories, L'Oreal, Nestle, General Mills, Omron, Philips, J&J - Yahoo Finance UK
Cardiac Marker Testing Market Is Going to Boom | Roche • Abbott - openPR.com
Abbott Laboratories Secures Major Acquisition with Shareholder Approval - AD HOC NEWS
Abbott Laboratories $ABT Shares Sold by Tredje AP fonden - MarketBeat
Siligmueller & Norvid Wealth Advisors LLC Purchases Shares of 11,538 Abbott Laboratories $ABT - MarketBeat
Raiffeisen Bank International AG Purchases 33,095 Shares of Abbott Laboratories $ABT - MarketBeat
China Universal Asset Management Co. Ltd. Sells 15,607 Shares of Abbott Laboratories $ABT - MarketBeat
Rep. Thomas H. Kean, Jr. Purchases Shares of Abbott Laboratories (NYSE:ABT) - MarketBeat
Pay Less, Gain More: STE, RMD Top Abbott Laboratories Stock - Trefis
Exact Sciences shareholders approve merger with Abbott Laboratories - Investing.com Australia
Decoding Abbott Laboratories (ABT): A Strategic SWOT Insight - GuruFocus
Exact Sciences shareholders approve merger with Abbott Laboratories By Investing.com - Investing.com India
Abbott Laboratories (ABT) Announces Positive Results for Amulet 360 Left Atrial Appendage (LAA) Occlude - Finviz
Abbott Laboratories (ABT) Announces Board of Directors Restructu - GuruFocus
Thomas Kean Jr makes strategic moves in Abbott Laboratories and General Motors - Investing.com Australia
Exact Sciences stockholders approve acquisition by Abbott - marketscreener.com
Exact Sciences Shareholders Approve Merger with Abbott Laboratories - TipRanks
Abbott Laboratories Streamlines Governance With Smaller Board - TipRanks
Abbott (ABT) to Acquire Exact Sciences Following Stockholder App - GuruFocus
Exact Sciences Shareholders Approve Acquisition by Abbott Laboratories - marketscreener.com
ABBOTT LABORATORIES SEC 10-K Report - TradingView
Cancer test provider Exact Sciences gets $105-a-share Abbott deal - Stock Titan
Abbott Laboratories (ABT) Maintains Quarterly Dividend - GuruFocus
Abbott declares 63-cent quarterly dividend, 409th consecutive - Investing.com
Abbott Laboratories Declares Quarterly Cash Dividend, Payable on May 15, 2026 - marketscreener.com
Abbott Keeps Quarterly Dividend at $0.63 a Share, Payable May 15 to Holders of Record as of April 15 - marketscreener.com
Abbott Laboratories Stock (ABT) Financials Data
Revenue
Net Income
Cash Flow
EPS
1.19%
0.89%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):